Literature DB >> 11690675

Salvage radiotherapy for PSA failure after radical prostatectomy.

C Parker1, P Warde, C Catton.   

Abstract

BACKGROUND AND
PURPOSE: Prostate-specific antigen (PSA) failure after radical prostatectomy is a common clinical scenario, and there is no consensus on how it should be managed. Salvage radiation to the prostatic bed is a potentially curative treatment option, and is the subject of this review. Patient selection, and the efficacy and toxicity of treatment will be discussed, and recommendations made for current practice and future studies.
METHODS: An English language MEDLINE search was performed, limited to the years 1989-2000, using the MeSH headings 'prostatic neoplasms' and 'radiotherapy'. The 660 abstracts identified were reviewed, and articles concerning patient selection for, or outcome of, post-operative radiation to the prostatic bed selected. After exclusion of articles concerning adjuvant, rather than salvage, radiation, this left a total of 22 case series, including 1062 patients for the review of treatment efficacy. RESULTS AND
CONCLUSIONS: The quality of the evidence makes it difficult to form a judgment regarding the efficacy of salvage radiation following radical prostatectomy, particularly in men with a PSA level in the range 0.01-0.2 ng/ml. Salvage radiation may be more effective given earlier rather than later. These considerations have important consequences for the interpretation of current trials of adjuvant radiation following radical prostatectomy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11690675     DOI: 10.1016/s0167-8140(01)00439-x

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting.

Authors:  Michael Sia; Tom Pickles; Gerard Morton; Louis Souhami; Himu Lukka; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2008-10       Impact factor: 1.862

2. 

Authors:  Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

3.  Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer.

Authors:  Michael Sia; George Rodrigues; Cynthia Menard; Andrew Bayley; Robert Bristow; Peter Chung; Mary Gospodarowicz; Michael Milosevic; Padraig Warde; Charles Catton
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

4.  Radiation therapy after radical prostatectomy: why patience is a virtue! The case for salvage radiation therapy.

Authors:  Kevin M Slawin
Journal:  Rev Urol       Date:  2002

Review 5.  [Delays and treatment interruptions: difficulties in administering radiotherapy in an ideal time-period].

Authors:  Carmen González San Segundo; Felipe A Calvo Manuel; Juan Antonio Santos Miranda
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

6.  Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy.

Authors:  Natsuo Tomita; Takeshi Kodaira; Kazuhisa Furutani; Hiroyuki Tachibana; Rie Nakahara; Nobutaka Mizoguchi; Norio Hayashi
Journal:  J Cancer Res Clin Oncol       Date:  2009-05-29       Impact factor: 4.553

Review 7.  Salvage radiotherapy following radical prostatectomy.

Authors:  Charles Catton; Michael Milosevic
Journal:  World J Urol       Date:  2003-08-16       Impact factor: 4.226

8.  Survival analysis of patients with biochemical relapse after radical prostatectomy treated with androgen deprivation: Castration-resistance influential factors.

Authors:  Rubén Algarra; Mateo Hevia; Antonio Tienza; Imanol Merino; José María Velis; Javier Zudaire; José Enrique Robles; Ignacio Pascual
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

9.  Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer.

Authors:  C C Parker; A R Norman; R A Huddart; A Horwich; D P Dearnaley
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

10.  A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).

Authors:  Roche Kapoor; Matthew P Deek; Riley McIntyre; Natasha Raman; Megan Kummerlowe; Iyah Chen; Matt Gaver; Hao Wang; Sam Denmeade; Tamara Lotan; Channing Paller; Mark Markowski; Michael Carducci; Mario Eisenberger; Tomasz M Beer; Daniel Y Song; Theodore L DeWeese; Jason W Hearn; Stephen Greco; Curtiland DeVille; Neil B Desai; Elisabeth I Heath; Stanley Liauw; Daniel E Spratt; Arthur Y Hung; Emmanuel S Antonarakis; Phuoc T Tran
Journal:  BMC Cancer       Date:  2019-06-13       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.